Form S-8 Sage Therapeutics, Inc.
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Oppenheimer Reiterates Perform Rating on Sage Therapeutics (SAGE)
August 7, 2023 4:56 PM EDTOppenheimer analyst Jay Olson reiterated a Perform rating and $20.00 price target on Sage Therapeutics (NASDAQ: SAGE)
The analyst comments "SAGE is focused on delivering newly-approved Zurzuvae to PPD patients while accelerating development of pipeline assets and rationalizing OpEx spending. We... More



